An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

19, Pfizer announced it was entering into a licensing agreement with 3SBio, a China-based biotech ... particularly thanks to its $43 billion acquisition of the smaller cancer specialist Seagen.

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...